



COMPANY CONTACT:
investor@laterion.com
TEL: 510.350.7870

IATERION, INC. ANNOUNCES PATRICK SUEL, M.SC., JOINS ITS BOARD OF DIRECTORS

Patrick Suel brings over 18 years of experience establishing and managing international Corporate VC funds. Prior to entering the Venture Capital world, he worked in various positions with multiple Software startups in Silicon Valley from Artificial Intelligence to Financial Services or Software Tools and Learning. He was also an entrepreneur, founding companies on the Internet, Biotechnology and Medical Devices fields. Patrick established Diamond Edge Ventures, the CVC arm of Mitsubishi Chemical Holdings Corporation in 2018 after a long tenure at Panasonic Ventures. Besides his CVC practice know-how, he brings to laterion a unique combination of innovation ecosystem network, technical expertise, business acumen and international experience that the companies in his portfolio value. Patrick earned a MSc. In Physics followed by a MSc. in Artificial Intelligence.

“I’m enthusiastic to join laterion’s Board of Directors,” said Mr. Suel. “laterion is an innovative biopharmaceutical company with substantial discoveries in the field of molecular endocrinology. I see great potential with laterion’s current drug candidates for Women’s Health as well as with their nuclear receptors modulating platform. Their recent publication concerning the nuclear receptor reprogramming ligands may help solve long issues where steroid hormones are involved”.

laterion, Inc. identified multiple compounds with high potency and selectivity to modulate hormone activity. These drugs include receptor sub-type and tissue specific drugs as well as reprogramming agents which alter the natural hormone’s pharmacology.

“We are excited to add Mr. Suel as a Board of Director” said Dr. Isaac Cohen, laterion’s CEO. “Patrick brings a wealth of knowledge and experience from the business world as a VC, founder of companies and as an experienced board member. We believe his help will be fundamental to the company’s progress”.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of laterion, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as

□□□



COMPANY CONTACT:
investor@iaterion.com
TEL: 510.350.7870

anticipated, believed, estimated or expected. Iaterion, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

